Literature DB >> 16413609

Rapid actions of aldosterone in vascular health and disease--friend or foe?

Ole Skøtt1, Torben R Uhrenholt, Jeppe Schjerning, Pernille B L Hansen, Lasse E Rasmussen, Boye L Jensen.   

Abstract

The mineralocorticoid receptor (MR) and the enzyme 11betahydroxysteroid dehydrogenase type 2, which confers aldosterone specificity to the MR, are present in endothelium and vascular smooth muscle. In several pathological conditions aldosterone promotes vascular damage by formation of reactive oxygen species. The effect of aldosterone on vascular function, however, is far from clear. By rapid non-genomic mechanisms aldosterone may cause calcium mobilization and vasoconstriction, or may stimulate nitric oxide formation through the PI-3 kinase/Akt pathway and thereby counteract vasoconstriction. Vasoconstrictor, vasodilator or no effects of aldosterone have been reported from studies on human forearm blood flow. Inhibition of MR with spironolactone improves endothelial function in patients with heart failure but worsens endothelial function in type 2 diabetic patients. The aim of the present review is to reconcile some of the apparently conflicting data. A key observation is that reactive oxygen and nitrogen species serve as physiological signaling molecules at low concentrations, while they initiate pathological processes at higher concentrations. The net effect of aldosterone, which stimulates ROS production, therefore depends on the ambient level of oxidative stress. Thus, in situations with low levels of oxidative stress aldosterone may promote vasodilatation, while at higher oxidative stress (high NaCl intake, pre-existing vascular pathological conditions, high oxygen tension in vitro) aldosterone is likely to be associated with vasoconstriction and oxidative damage, and in this setting inhibition of the MR is likely to be beneficial.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16413609     DOI: 10.1016/j.pharmthera.2005.10.010

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  14 in total

1.  Low doses of fludrocortisone and hydrocortisone, alone or in combination, on vascular responsiveness to phenylephrine in healthy volunteers.

Authors:  Bruno Laviolle; Erwan Donal; Pascale Le Maguet; Fabrice Lainé; Eric Bellissant
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

Review 2.  Mineralocorticoid receptors in vascular function and disease.

Authors:  Amy McCurley; Iris Z Jaffe
Journal:  Mol Cell Endocrinol       Date:  2011-06-24       Impact factor: 4.102

3.  Mineralocorticoid accelerates transition to heart failure with preserved ejection fraction via "nongenomic effects".

Authors:  Selma F Mohammed; Tomohito Ohtani; Josef Korinek; Carolyn S P Lam; Katarina Larsen; Robert D Simari; Maria L Valencik; John C Burnett; Margaret M Redfield
Journal:  Circulation       Date:  2010-07-12       Impact factor: 29.690

Review 4.  Aldosterone and arterial hypertension.

Authors:  Andreas Tomaschitz; Stefan Pilz; Eberhard Ritz; Barbara Obermayer-Pietsch; Thomas R Pieber
Journal:  Nat Rev Endocrinol       Date:  2009-12-22       Impact factor: 43.330

5.  The selective mineralocorticoid receptor antagonist eplerenone prevents decompensation of the liver in cirrhosis.

Authors:  Barbara Schreier; Anja Wolf; Stefanie Hammer; Sabine Pohl; Sigrid Mildenberger; Sindy Rabe; Michael Gekle; Alexander Zipprich
Journal:  Br J Pharmacol       Date:  2018-06-07       Impact factor: 8.739

Review 6.  The endothelial mineralocorticoid receptor: mediator of the switch from vascular health to disease.

Authors:  Ana P Davel; Imran J Anwar; Iris Z Jaffe
Journal:  Curr Opin Nephrol Hypertens       Date:  2017-03       Impact factor: 2.894

Review 7.  Direct contribution of vascular mineralocorticoid receptors to blood pressure regulation.

Authors:  Kathleen V Barrett; Amy T McCurley; Iris Z Jaffe
Journal:  Clin Exp Pharmacol Physiol       Date:  2013-12       Impact factor: 2.557

8.  Aldosterone activates transcription factor Nrf2 in kidney cells both in vitro and in vivo.

Authors:  Nina Queisser; Patricia I Oteiza; Samuel Link; Valentin Hey; Helga Stopper; Nicole Schupp
Journal:  Antioxid Redox Signal       Date:  2014-03-21       Impact factor: 8.401

9.  Actions of aldosterone in the cardiovascular system: the good, the bad, and the ugly?

Authors:  Michael Gekle; Claudia Grossmann
Journal:  Pflugers Arch       Date:  2008-11-19       Impact factor: 3.657

10.  Acute effect of mineralocorticoid receptor antagonism on vascular function in healthy older adults.

Authors:  Moon-Hyon Hwang; Jeung-Ki Yoo; Meredith Luttrell; Han-Kyul Kim; Thomas H Meade; Mark English; Susanne Talcott; Iris Z Jaffe; Demetra D Christou
Journal:  Exp Gerontol       Date:  2015-11-27       Impact factor: 4.032

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.